AstraZeneca Zomig-ZMT new strength
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves 5 mg strength of the orally disintegrating tablet Zomig-ZMT for acute treatment of migraine on Sept. 17. The disintegrating tablet was first approved Feb. 13 in a 2.5 mg strength